ARCH Venture Management, LLC reported 12 holdings worth US$1.1B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
ARCH Venture Management, LLC reported 12 holdings worth US$1.1B as of Jun 30, 2026. Largest: Parabilis Medicines, Inc., Beam Therapeutics Inc. and Rapport Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 12
- Value as reported
- US$1.1B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Parabilis Medicines, Inc. | 6.41M | US$176M | 16.0% |
| Beam Therapeutics Inc. | 4.54M | US$156M | 14.2% |
| Rapport Therapeutics, Inc. | 3.73M | US$155M | 14.1% |
| Seaport Therapeutics, Inc. | 6.29M | US$137M | 12.4% |
| Erasca, Inc. | 7.09M | US$130M | 11.8% |
| Vir Biotechnology, Inc. | 12.7M | US$129M | 11.8% |
| Maze Therapeutics, Inc. | 4.12M | US$123M | 11.2% |
| Lyell Immunopharma, Inc. | 3.25M | US$45.5M | 4.1% |
| Generate Biomedicines, Inc. | 1.94M | US$32.8M | 3.0% |
| 10x Genomics, Inc. | 218K | US$8.35M | 0.76% |
| Boundless Bio, Inc. | 2.69M | US$6.74M | 0.61% |
| Gossamer Bio, Inc. | 8.06M | US$1.33M | 0.12% |
| Q32 Bio Inc. | 0 | US$0 | 0.00% |